Research ArticleOriginal Article

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

Nanhui Chen, Zengjun Wang, Ming Chen, Qi Ma, Yi He, Yujie Wang, Xin Li, Mingxing Qiu, Lei Shi, Shaoxing Zhu, Qun Xie, Xiuheng Liu, Benkang Shi, Guowen Lin, Weizhong Yang, Yongbin Liao, Haibin Zhang, Shusheng Wang, Jiexian Li, Shaogang Wang, Lijun Dong, Hui Chen, Jiaju Lu, Yongyi Cheng, Xiaoping Zhang, Lulin Ma, Liqun Zhou, He Wang, Shen Li and Dingwei Ye
Cancer Biology & Medicine December 2023, 20 (12) 1047-1059; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0335

References

  1. 1.↵
    2. Sung H,
    3. Ferlay J,
    4. Siegel RL,
    5. Laversanne M,
    6. Soerjomataram I,
    7. Jemal A, et al.
    Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Wang F,
    3. Wang C,
    4. Xia H,
    5. Lin Y,
    6. Zhang D,
    7. Yin P, et al.
    Burden of prostate cancer in China, 1990-2019: findings from the 2019 Global Burden of Disease Study. Front Endocrinol (Lausanne). 2022; 13: 853623.
  3. 3.↵
    2. Chen R,
    3. Sjoberg DD,
    4. Huang Y,
    5. Xie L,
    6. Zhou L,
    7. He D, et al.
    Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with western cohorts. J Urol. 2017; 197: 90–6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Zhang L,
    3. Liu X,
    4. Xia R,
    5. Chen F,
    6. Wang X,
    7. Bao J, et al.
    Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations. Pathol Res Pract. 2022; 234: 153933.
  5. 5.↵
    2. Siegel DA,
    3. O’Neil ME,
    4. Richards TB,
    5. Dowling NF,
    6. Weir HK.
    Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020; 69: 1473–80.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Xu L,
    3. Wang J,
    4. Guo B,
    5. Zhang H,
    6. Wang K,
    7. Wang D, et al.
    Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China. Oncotarget. 2018; 9: 428–41.
    OpenUrl
  7. 7.↵
    Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology: Prostate Cancer. People’s Medical Publishing House; 2021.
  8. 8.↵
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. (Version 3. 2022), 2022. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459.
  9. 9.
    2. Parker C,
    3. Castro E,
    4. Fizazi K,
    5. Heidenreich A,
    6. Ost P,
    7. Procopio G, et al.
    Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1119–34.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Wang Q,
    3. Li Z,
    4. Yang J,
    5. Peng S,
    6. Zhou Q,
    7. Yao K, et al.
    Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer. Cancer Biol Med. 2021; 19: 1193–210.
    OpenUrl
  11. 11.↵
    2. Seidenfeld J,
    3. Samson DJ,
    4. Hasselblad V,
    5. Aronson N,
    6. Albertsen PC,
    7. Bennett CL, et al.
    Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000; 132: 566–77.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    2. Weiner AB,
    3. Cohen JE,
    4. DeLancey JO,
    5. Schaeffer EM,
    6. Auffenberg GB.
    Surgical versus medical castration for metastatic prostate cancer: use and overall survival in a national cohort. J Urol. 2020; 203: 933–9.
    OpenUrl
  13. 13.↵
    2. Selvi I,
    3. Basar H.
    Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects. Support Care Cancer. 2020; 28: 4313–26.
    OpenUrl
  14. 14.↵
    2. Schally AV,
    3. Block NL,
    4. Rick FG.
    Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate. 2017; 77: 1036–54.
    OpenUrl
  15. 15.↵
    2. Debruyne FM,
    3. Dijkman GA,
    4. Lee DC,
    5. Witjes WP,
    6. del Moral F,
    7. Karthaus HF, et al.
    A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol. 1996; 155: 1352–4.
    OpenUrlPubMed
  16. 16.↵
    2. Gu W,
    3. Ye D.
    A survey of urologists on gonadotropin-releasing hormone agonist therapy for prostate cancer. Chin J Urol. 2021; 42: 747–51.
    OpenUrl
  17. 17.↵
    2. Dijkman GA,
    3. Debruyne FM,
    4. Fernandez del Moral P,
    5. Plasman JW,
    6. Hoefakker JW,
    7. Idema JG, et al.
    A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. Eur Urol. 1995; 27: 43–6.
    OpenUrlPubMed
  18. 18.↵
    2. Fernandez del Moral P,
    3. Dijkman GA,
    4. Debruyne FM,
    5. Witjes WP,
    6. Kolvenbag GJ.
    Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology. 1996; 48: 894–900.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Ishizuka O,
    3. Nishizawa O,
    4. Nishizawa S,
    5. Satoh T,
    6. Wajiki M,
    7. Kiyokawa H, et al.
    Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. Int J Clin Oncol. 2013; 18: 524–30.
    OpenUrl
  20. 20.↵
    2. Sarosdy MF,
    3. Schellhammer PF,
    4. Soloway MS,
    5. Vogelzang NJ,
    6. Crawford ED,
    7. Presti J, et al.
    Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int. 1999; 83: 801–6.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Zinner NR,
    3. Bidair M,
    4. Centeno A,
    5. Tomera K.
    Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology. 2004; 64: 1177–81.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Ma S,
    3. Zhang J,
    4. Su X,
    5. Fan X,
    6. Jiao J,
    7. Cui C, et al.
    Risk factor analysis of patients with biochemical recurrence after radical prostatectomy. Chin J Urol. 2022; 43: 35–9.
    OpenUrl
  23. 23.↵
    2. Fontana D,
    3. Mari M,
    4. Martinelli A,
    5. Boccafoschi C,
    6. Magno C,
    7. Turriziani M, et al.
    3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int. 2003; 70: 316–20.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Kaisary AV,
    3. Tyrrell CJ,
    4. Peeling WB,
    5. Griffiths K.
    Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991; 67: 502–8.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    2. Shore ND,
    3. Saad F,
    4. Cookson MS,
    5. George DJ,
    6. Saltzstein DR,
    7. Tutrone R, et al.
    Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020; 382: 2187–96.
    OpenUrl
  26. 26.↵
    2. Shim M,
    3. Bang WJ,
    4. Oh CY,
    5. Lee YS,
    6. Cho JS.
    Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 2019; 60: 244–50.
    OpenUrl
  27. 27.↵
    2. Saad F,
    3. Fleshner N,
    4. Pickles T,
    5. Niazi T,
    6. Lukka H,
    7. Pouliot F, et al.
    Testosterone breakthrough rates during androgen deprivation therapy for castration sensitive prostate cancer. J Urol. 2020; 204: 416–26.
    OpenUrl
  28. 28.↵
    2. Wilke D,
    3. Patil N,
    4. Hollenhorst H,
    5. Bowes D,
    6. Rutledge R,
    7. Ago C.
    Testosterone suppression with luteinizing hormone-releasing hormone (LHRH) agonists in patients receiving radiotherapy for prostate cancer. Pharmacotherapy. 2018; 38: 327–33.
    OpenUrl
  29. 29.↵
    2. Berrondo C,
    3. Feng C,
    4. Kukreja JB,
    5. Messing EM,
    6. Joseph JV.
    Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: a prospective randomized clinical trial. Urol Oncol. 2019; 37: 181.e7–e14.
    OpenUrl
  30. 30.↵
    2. Guillonneau B,
    3. Vallancien G.
    Laparoscopic radical prostatectomy: the Montsouris experience. J Urol. 2000; 163: 418–22.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    2. Mottet N,
    3. Cornford P,
    4. van den Bergh RCN,
    5. Briers E; European Prostate Cancer Coalition/Europa UOMO,
    6. de Santis M, et al.
    EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Eur Assoc Urol. 2022. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022.pdf.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords